FN2102 A randomized, prospective, double-blind, placebo controlled, phase 3 study of study drug prophylaxis as a supplement to standard of care prophylaxis to prevent Read more about FN2102 A randomized, prospective, double-blind, placebo controlled, phase 3 study of study drug prophylaxis as a supplement to standard of care prophylaxis to prevent
A Phase III, Open-Label, Multi-Center, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients with AML Read more about A Phase III, Open-Label, Multi-Center, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients with AML
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care Read more about A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care
A Randomized Phase 2/3 Study of DACOGEN (Decitabine) Plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML... Read more about A Randomized Phase 2/3 Study of DACOGEN (Decitabine) Plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML...
A Randomized Phase 2/3 Study of DACOGEN (Decitabine) Plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML... Read more about A Randomized Phase 2/3 Study of DACOGEN (Decitabine) Plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML...
A Randomized Phase 2/3 Study of DACOGEN (Decitabine) Plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML... Read more about A Randomized Phase 2/3 Study of DACOGEN (Decitabine) Plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML...
A Randomized Phase 2/3 Study of DACOGEN (Decitabine) Plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML... Read more about A Randomized Phase 2/3 Study of DACOGEN (Decitabine) Plus JNJ-56022473 (Anti-CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML...
